WesBanco Bank’s Corcept Therapeutics CORT Stock Holding History

WesBanco Bank’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23,152	Closed	-$631K	–	422
2023 Q3	$631K	Hold	23,152	–	–	0.03%	364
2023 Q2	$515K	Sell	23,152 -279	-1%	-$6.42K	0.02%	403
2023 Q1	$508K	Hold	23,431	–	–	0.02%	412
2022 Q4	$476K	Buy	+23,431	New	+$587K	0.02%	408

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

WesBanco Bank's CORT Position: Q4 2023 in Review

WesBanco Bank sold out of Corcept Therapeutics (CORT) in Q4 2023, closing a stake of 23,152 shares — an estimated $631K sold.

WesBanco Bank first reported a position in CORT in Q4 2022 and held it in 4 quarters. The position peaked at $631K in Q3 2023. 273 funds tracked by Wall St. Rank hold CORT as of Q4 2023.

WesBanco Bank reported no remaining Corcept Therapeutics position as of Q4 2023 after selling out during the quarter.
WesBanco Bank sold 23,152 Corcept Therapeutics shares in Q4 2023, an estimated $631K.
WesBanco Bank first reported a position in Corcept Therapeutics in Q4 2022 and held it in 4 quarters.
WesBanco Bank's Corcept Therapeutics position peaked at $631K in Q3 2023.
273 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2023.

Based on WesBanco Bank's 13F filing for Q4 2023, filed 16 Feb 2024.